Comparison of fleroxacin and penicillin G plus probenecid in the treatment of acute uncomplicated gonococcal infections
- PMID: 1427804
- PMCID: PMC1195987
- DOI: 10.1136/sti.68.5.317
Comparison of fleroxacin and penicillin G plus probenecid in the treatment of acute uncomplicated gonococcal infections
Abstract
Objective: To investigate the activity of fleroxacin in acute uncomplicated infections with N. gonorrhoeae in comparison with conventional penicillin G plus probenecid treatment.
Design: Multicentre open label randomised parallel group study.
Subjects: Male patients aged 18 years or over from university departments of urology, epidemiology and dermatology and a clinic for sexually transmitted diseases.
Interventions: Two hundred and sixty male patients were randomly assigned to treatment with either a single oral dose of fleroxacin 400 mg (130 patients) or a single intramuscular dose of penicillin G (2.4 or 5.0 mega units) plus a single oral dose of probenecid 1 gram (130 patients). Efficacy and safety assessments were undertaken at follow-up (3-14 days after treatment). Efficacy was assessed as bacteriological outcome of treatment. Safety was assessed by evaluation of adverse events, laboratory abnormalities and changes in vital signs.
Results: Two hundred and twenty four patients (114 in the fleroxacin group and 110 in the penicillin plus probenecid group) were evaluated for efficacy. Bacteriological cures were achieved in 100% of patients in the fleroxacin group and 97% of patients in the penicillin plus probenecid group. There was no statistically significant difference between the two groups in this respect (Fisher exact test, p = 0.25). Clinical cures were achieved in 100% of patients receiving fleroxacin and 95% of patients receiving penicillin plus probenecid. Safety analyses were undertaken on 255 patients (126 in the fleroxacin group and 129 in the penicillin plus probenecid group). No adverse events were reported for either treatment group, and no clinically relevant laboratory abnormalities were apparent. Thus, there appeared to be no difference in the efficacy or safety of these two treatments when used to treat acute, uncomplicated urethral gonorrhoea in males.
Conclusions: In this study fleroxacin proved to be highly effective therapy for uncomplicated gonococcal urethritis in males and may provide a favourable alternative to standard treatment.
Similar articles
-
Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.Drugs. 1995 May;49(5):794-850. doi: 10.2165/00003495-199549050-00010. Drugs. 1995. PMID: 7601015 Review.
-
Fleroxacin versus standard therapy in gonococcal urethritis.J Antimicrob Chemother. 1988 Oct;22 Suppl D:223-5. doi: 10.1093/jac/22.supplement_d.223. J Antimicrob Chemother. 1988. PMID: 3144542 Clinical Trial.
-
Evaluation of treatment with single-dose ampicillin/sulbactam with probenecid or ceftriaxone in patients with uncomplicated gonorrhea.Sex Transm Dis. 1992 Nov-Dec;19(6):341-5. Sex Transm Dis. 1992. PMID: 1492262 Clinical Trial.
-
Three regimens of procaine penicillin G, Augmentin, and probenecid compared for treating acute gonorrhoea in men.Genitourin Med. 1986 Apr;62(2):82-5. doi: 10.1136/sti.62.2.82. Genitourin Med. 1986. PMID: 3721514 Free PMC article.
-
Addition of probenecid to oral β-lactam antibiotics: a systematic review and meta-analysis.J Antimicrob Chemother. 2022 Aug 25;77(9):2364-2372. doi: 10.1093/jac/dkac200. J Antimicrob Chemother. 2022. PMID: 35726853 Free PMC article.
Cited by
-
Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.Drugs. 1995 May;49(5):794-850. doi: 10.2165/00003495-199549050-00010. Drugs. 1995. PMID: 7601015 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical